3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
53
Neoplasm Metastasis
6
Endometrial Neoplasms
5
Polycystic Ovary Syndrome
4
Ovarian Neoplasms
4
Neoplasms
4
Advanced Breast Cancer
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Neoplasms by Site
2
Infertility
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sexual Dysfunctions, Psychological
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Interventions
pembrolizumab
27
Cisplatin
18
Cetuximab
12
Carboplatin
12
Surveys and Questionnaires
8
Radiotherapy
8
Paclitaxel
8
Docetaxel
6
Radiotherapy, Intensity-Modulated
5
Surgical Procedures, Operative
4
dostarlimab
3
Therapeutics
3
Standard of Care
3
Fluorouracil
3
Cyclophosphamide
3
Chemoradiotherapy
3
Blood Specimen Collection
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
nimotuzumab
2
fludarabine
2
durvalumab
2
atezolizumab
2
abemaciclib
2
X-Rays
2
Taxes
2
Radiosurgery
2
Radiation
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Letrozole
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled